(b)(4).During processing of this complaint, attempts were made to obtain complete event, patient and device information.The device was not returned for evaluation.The lot history record (lhr) for this product could not be reviewed because the product was not returned for evaluation and the lot number was not reported.Based on the case information and related record review, a conclusive cause for the reported patient effect(s), and the relationship to the product, if any, cannot be determined.The reported patient effects of stroke, neurologic symptoms, visual disturbances and weakness are listed in the xact instruction for use as known potential adverse effects.There is no indication of a product quality issue with respect to manufacture, design or labeling.
|
It was reported that this was a procedure to treat a lesion in the internal carotid artery and common carotid artery.An emboshield nav 6 embolic protection system was advanced and deployed.A 4x30 mm viatrac dilatation catheter was used for pre-dilatation.A xact 8tx40x136 carotid stent system was advanced and deployed without any issue in the internal carotid artery.A 6-8 x 40 mm acculink stent system was advanced and deployed successfully in the common carotid artery; a 6x30x135 viatrac plus dilatation catheter was used for post dilatation.Upon completion of the procedure, after the emboshield nav 6 was removed; the patient experienced facial drooping, right side motor function loss, and incoherent speech.The patient had a stroke.Medication was used for treatment and the symptoms resolved.It is the physicians opinion that the stroke and symptoms are not related to the xact stent but are related to radiation the patient previously received for a neck tumor.The patient remains hospitalized, but in stable condition.No additional information was provided.
|